Business
Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
Company announcement No. 13 / 2026 Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program Robust cash position of USD 2.3 billion (DKK 14.5 billion) as of March 31, 2026Financial strength to be further enhanced by significant milestone payments of USD 700 million from Roche in 2026Continuing to invest significantly in research capabilities to build a leading metabolic health pipeline and execute on Metabolic Frontier 2030 strategy Copenhagen, Denmark, May 7, 2026 – Zea
About this update from Zealand Pharma A/s
[{"type":"image","alt":"Zealand Pharma","displaySize":"","headline":null,"caption":"Zealand Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":121,"url":"https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hruCjDK29WWlg5.YGk148A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OQ--/https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff","width":300,"height":121},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/hruCjDK29WWlg5.YGk148A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OQ--/https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff","width":300,"height":121}},"lazy":false},{"type":"text","content":"Company announcement No. 13 / 2026","length":34,"tagName":"p"},{"type":"text","content":"Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program","length":81,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Robust cash position of USD 2.3 billion (DKK 14.5 billion) as of March 31, 2026","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Financial strength to be further enhanced by significant milestone payments of USD 700 million from Roche in 2026","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"Continuing to invest significantly in research capabilities to build a leading metabolic health pipeline and execute on Metabolic Frontier 2030 strategy","length":152,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":344,"olType":false},{"type":"text","content":"Copenhagen, Denmark, May 7, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces that it has decided to initiate a share buy-back program (the “Program”), under which the Company will buy back own shares for a maximum total consideration of DKK 1.3 billion and a maximum of 7,152,557 shares. The Program will run from May 7, 2026, up to and including October 31, 2026, unless it is terminated or suspended earlier by the Company. Danske Bank will act as lead manager and, at its discretion, may complete the Program prior to the end of the stated period. The Program will be implemented in accordance with Regulation (EU) No 596/2014...